TITLE

DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes

AUTHOR(S)
Sang Ah Lee
PUB. DATE
September 2013
SOURCE
Journal of Korean Diabetes;2013, Vol. 14 Issue 3, p128
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Dipeptidylpeptidase-4 (DPP-4) inhibitors are new glucose-lowering agents with mechanisms that differ from those of previous oral hypoglycemic agents (OHAs). DPP-4 inhibitors have shown a continuous glucose lowering effect (> 0.5%) when used in monotherapy as well as when used in combination with metformin, sulfonylurea, thiazolidinedione (TZD), insulin, and any other drug. In addition to improving glucose control, DPP-4 inhibitors have also shown a neutral effect on weight gain, improved β-cell function, and lowered the risk of hypoglycemia. Because of these advantages, DPP-4 inhibitors are widely used in the treatment of all patients with type 2 diabetes mellitus, but especially elderly patients. Therefore, more information regarding these strengths of DPP-4 inhibitors will lead to better treatment of patients with T2DM.
ACCESSION #
93393932

 

Related Articles

  • Teneligliptin: A Review in Type 2 Diabetes. Scott, Lesley // Clinical Drug Investigation;Nov2015, Vol. 35 Issue 11, p765 

    Oral teneligliptin [Teneglucon (Argentina)], a dipeptidyl peptidase-4 inhibitor, is indicated for the treatment of adults with type 2 diabetes (T2DM). This article reviews the pharmacology, therapeutic efficacy and tolerability of teneligliptin in the treatment of adults with T2DM. In 12- or...

  • Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors. Omar, Bilal; Ahrén, Bo // Diabetes;Jul2014, Vol. 63 Issue 7, p2196 

    Dipeptidyl peptidase (DPP)-4 inhibition is a glucose-lowering treatment for type 2 diabetes. The classical mechanism for DPP-4 inhibitors is that they inhibit DPP-4 activity in peripheral plasma, which prevents the inactivation of the incretin hormone glucagon-like peptide (GLP)-1 in the...

  • Metformin Associated with Less Need for a Second Medicine. SHAUGHNESSY, ALLEN F. // American Family Physician;2/15/2015, Vol. 91 Issue 4, p261 

    The article discusses a study which investigated the initial treatment of type 2 diabetes using oral hypoglycemics other than metformin. Topics discussed include possible cardiovascular event in patients that initially took a sulfonylurea, higher cost of treatment associated with...

  • Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes. SOLIS-HERRERA, CAROLINA; TRIPLITT, CURTIS; DE JESÚS GARDUNO-GARCIA, JOSE; ADAMS, JOHN; DEFRONZO, RALPH A.; CERSOSIMO, EUGENIO // Diabetes Care;Sep2013, Vol. 36 Issue 9, p2756 

    OBJECTIVE--To assess glucose-lowering mechanisms of sitagliptin (S), metformin (M), and the two combined (M+S). RESEARCH DESIGN AND METHODS--We randomized 16 patients with type 2 diabetes mellitus (T2DM) to four 6-week treatments with placebo (P), M, S, and M+S. After each period, subjects...

  • Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients. Hiroyuki Konya; Yuzo Yano; Satoshi Matsutani; Taku Tsunoda; Takashi Ikawa; Yoshiki Kusunoki; Toshihiro Matsuo; Masayuki Miuchi; Tomoyuki Katsuno; Tomoya Hamaguchi; Jun-ichiro Miyagawa; Mitsuyoshi Namba // Therapeutics & Clinical Risk Management;2014, Vol. 10, p547 

    Saxagliptin is a selective and potent dipeptidyl peptidase (DPP)-4 inhibitor, approved as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mel-litus (T2DM) in the USA on July 2009, and had been launched globally in over 86 countries by September 2013. In patients...

  • Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus. Sung-Ho Kim; Jung-Hwa Yoo; Woo Je Lee; Cheol-Young Park // Diabetes & Metabolism Journal;Oct2016, Vol. 40 Issue 5, p339 

    Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease glucagon secretion, and contribute to reducing...

  • Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Fisman, Enrique Z.; Tenenbaum, Alexander // Cardiovascular Diabetology;9/29/2015, Vol. 14 Issue 1, p1 

    The traditional oral pharmacological therapy for type 2 diabetes mellitus (T2DM) has been based on the prescription of metformin, a biguanide, as first line antihyperglycemic agent world over. It has been demonstrated that after 3 years of treatment, approximately 50 % of diabetic patients could...

  • Saxagliptin. Dhillon, Sohita; Weber, Juliane // Drugs;2009, Vol. 69 Issue 15, p2103 

    â–´Saxagliptin and its active metabolite M2 are dipeptidyl peptidase-4 inhibitors that improve glycaemic control by preventing the inactivation of the incretin hormones glucagon-like peptide-l (GLP- 1) and glucose-dependent insulinotropic polypeptide. This increases GLP-l levels, stimulates...

  • Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It's Time to Move On! Genuth, Saul // Diabetes Care;Jan2015, Vol. 38 Issue 1, p170 

    The article discusses the research supporting the discontinuations of using sulfonylureas (SU) as a first-line add on to metformin in treating type 2 diabetes. Topics include the joint recommendations of the American Diabetes Association (ADA) and the European Association for the Study of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics